Literature DB >> 18037876

Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.

Stelvio Ballanti1, Elena Mastrodicasa, Niccolò Bolli, Flavia Lotti, Ilaria Capolsini, Laura Berchicci, Carla Merigiola, Giampiero Giordano, Antonio Tabilio.   

Abstract

BACKGROUND: A 68-year-old man diagnosed with primary plasma-cell leukemia was given thalidomide maintenance treatment for his disease. He had previously failed induction therapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone, but achieved complete remission after melphalan therapy. Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia. INVESTIGATIONS: Blood tests, peripheral blood smear, bone-marrow biopsy and aspirate, Holter electrocardiogram. DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment. MANAGEMENT: Thalidomide withdrawal, dexamethasone maintenance therapy, monthly oral courses of combined melphalan and prednisone, salvage therapy with bortezomib.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037876     DOI: 10.1038/ncponc1008

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  3 in total

Review 1.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 2.  Primary Plasma Cell Leukemia: Identity Card 2016.

Authors:  Pellegrino Musto; Vittorio Simeon; Katia Todoerti; Antonino Neri
Journal:  Curr Treat Options Oncol       Date:  2016-04

3.  Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.

Authors:  Joshua Richter; Natalia Neparidze; Lin Zhang; Shiny Nair; Tamara Monesmith; Ranjini Sundaram; Fred Miesowicz; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2012-10-24       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.